Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Moderate Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $56.50.

Several research analysts have issued reports on MNPR shares. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Chardan Capital assumed coverage on shares of Monopar Therapeutics in a research note on Monday. They set a “buy” rating and a $60.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd.

Monopar Therapeutics Stock Performance

Shares of MNPR traded up $0.40 during trading hours on Monday, hitting $33.26. The stock had a trading volume of 624 shares, compared to its average volume of 357,862. The company’s fifty day simple moving average is $37.30 and its 200 day simple moving average is $34.55. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market cap of $203.55 million, a P/E ratio of -9.56 and a beta of 1.00.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.27. As a group, sell-side analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares of the company’s stock, valued at $28,778,925. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC purchased a new position in Monopar Therapeutics during the 4th quarter worth $23,435,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics in the 4th quarter worth about $13,182,000. RA Capital Management L.P. bought a new stake in shares of Monopar Therapeutics during the fourth quarter valued at approximately $11,247,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.